The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Coronary interventions
Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry
Stefan Verheye1, MD, PhD; Adrian Wlodarczak2, MD; Piero Montorsi3, MD; Johan Bennett4, MD, PhD; Jan Torzewski5, MD; Michael Haude6, MD; Mathias Vrolix7, MD; Thomas Buck8, MD; Adel Aminian9, MD; Rene J. van der Schaaf10, MD; Amin Arrif Nuruddin11, MD; Michael K.Y. Lee12, MD
1. Interventional Cardiology, ZNA Cardiovascular Center Middelheim, Antwerp, Belgium; 2. Miedziowe Centrum Zdrowia S.A., Lublin, Poland; 3. Department of Clinical Sciences and Community Health, University of Milan and Centro Cardiologico Monzino, IRCCS, Milan, Italy; 4. Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium; 5. Cardiovascular Center Oberallgäu-Kempten, Kempten, Germany; 6. Medical Clinic I Städtische Kliniken Neuss Lukaskrankenhaus GmbH, Neuss, Germany; 7. Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; 8. Department of Cardiology, Klinikum Westfalen, Knappschaft KH, Dortmund, Germany; 9. Centre Hospitalier Universitaire de Charleroi, Department of Cardiology, Charleroi, Belgium; 10. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; 11. Institute Jantung Negara, Kuala Lumpur, Malaysia; 12. Division of Cardiology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China
Introduction
Magmaris® (Biotronik AG, Bülach, Switzerland) is a magnesium-based scaffold that has been successfully tested in 184 patients enrolled in the BIOSOLVE-II and BIOSOLVE-III studies [1,2. After gaining CE certification in June 2016, it was paramount to test this device in clinical routine to ensure a safe roll-out of this technology.
Methods
BIOSOLVE-IV is an international, single-arm, multicentre registry conducted in 86 centres. The first patient was enrolled in September 2016. Inclusion and exclusion criteria and endpoints are listed on ClinicalTrials.gov (NCT02817802).
Clinical follow-up was scheduled at six and 12 months, and annually up to five years (...
Sign in to read and download the full article
Forgot your password? No account yet?
Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Coronary interventionsNSTEMIStable CADStents and scaffolds
Read next article
Impact of aetiology of mitral regurgitation on outcome after Mitraclip: lessons learned from MitraSwiss Registry.
Latest news
AHEAD OF PRINT
Delayed hospitalisation in the MITRA-FR trial
FREE ARTICLE - Guillaume Leurent et al
May 25, 2022
EUROPCR LATE BREAKING
EuroPCR 2022 Late-breaking publications: watch the interviews with the authors!
May 23, 2022
NEW ISSUE
TAVI vs SAVR for bicuspid anatomies; PVR and TAVI; LAA thrombus trapping; crush techniques for bifurcation PCIs; stent elongation in POT and more
May 18, 2022
AHEAD OF PRINT
Complete cerebral protection during TAVI
FREE ARTICLE - Dariusz Jagielak et al
May 24, 2022
AHEAD OF PRINT
Outcomes of PCI for stent thrombosis
FREE ARTICLE - Mohamed O. Mohamed et al
May 24, 2022
EUROPCR LATE BREAKING
Changes in voice patterns for monitoring heart failure deterioration
FREE ARTICLE - Chaim Lotan et al
May 24, 2022
EUROPCR LATE BREAKING
SavvyWire in TAVI
FREE ARTICLE - Josep Rodés-Cabau et al
May 24, 2022